A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Smit, E. F., Berendsen, H. H., Piers, D. A., Smeets, J., Riva, A., Postmus, P. E.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 1992
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977612/
https://ncbi.nlm.nih.gov/pubmed/1313691
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki